Antiviral agent 35 is an orally effective influenza virus inhibitor that acts at the early stage of viral replication; it inhibits influenza virus-induced ROS accumulation, autophagy, and apoptosis, and suppresses RIG-I pathway-mediated inflammatory responses in a murine model of pulmonary infection; it also exhibits anti-H1N1 (A/Weiss/43) activity with an EC50 of 2.28 μM.